Belite Bio, Inc (BLTE)
NASDAQ: BLTE · IEX Real-Time Price · USD
33.43
-0.85 (-2.48%)
Apr 19, 2024, 4:30 PM EDT - Market closed

Company Description

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.

The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.

It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes.

Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Belite Bio, Inc
Belite Bio logo
Country United States
Founded 2018
IPO Date Apr 29, 2022
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.

Contact Details

Address:
12750 High Bluff Drive Suite 475
San Diego, California 92130
United States
Phone 858-246-6240
Website belitebio.com

Stock Details

Ticker Symbol BLTE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001889109
CUSIP Number 07782B104
ISIN Number US07782B1044
SIC Code 2834

Key Executives

Name Position
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors and Chief Executive Officer
Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. Chief Financial Officer and Director
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 22, 2024 144 Filing
Mar 22, 2024 6-K Report of foreign issuer
Mar 14, 2024 144 Filing
Mar 12, 2024 6-K Report of foreign issuer
Mar 12, 2024 20-F Annual and transition report of foreign private issuers
Mar 12, 2024 6-K Report of foreign issuer
Feb 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Dec 28, 2023 144 Filing
Dec 28, 2023 144 Filing